Navigation Links
Investor Call Scheduled to Discuss Ouster Proposal of Trinity Biotech Directors
Date:10/27/2008

KANSAS CITY, Mo., Oct. 27 /PRNewswire/ -- Thomas Reidy, an investor in Trinity Biotech plc (Nasdaq: TRIB), an Ireland-based developer and manufacturer of diagnostic products whose American Depository Receipts are traded on NASDAQ, will host an investor conference call November 3, 2008, at 10:00am EST, to discuss the recent shareholder proposal calling for the removal and replacement of Trinity Biotech's current directors.

On October 16, 2008, Mr. Reidy, and nine other shareholders, sent a letter to Trinity Biotech requesting that a special meeting of shareholders be held to consider the immediate removal of the current directors of Trinity Biotech. In the same letter, the investor group, who collectively hold beneficial ownership of more than 10% of Trinity Biotech's voting stock, directed that Trinity Biotech shareholders be given the opportunity to vote on the following slate of replacement directors:

-- Dr. Jack C. Chow, M.D., M.B.A. -- Partner, CRV Capital, LLC and adjunct

professor at Carnegie Mellon University's Heinz School of Public Policy

and Management;

-- Mr. Mike Gausling -- Managing Partner, Originate Ventures;

-- Dr. John H. Halsey, Ph.D. -- Chief Executive Officer, Director,

Founder, ProGene Biomedical, Inc. (dba IBT Laboratories);

-- Mr. Steven A. Mock, CPA -- Partner, BKD, LLP;

-- Mr. Thomas Reidy; and

-- Mr. Clint Severson -- Chairman, President and CEO of Abaxis, Inc.

According to Irish Law, Trinity Biotech must call a special meeting of shareholders, called an Extraordinary General Meeting, if the meeting is requested by shareholders holding in excess of 10% of the voting paid-up capital of the company.

The purpose of the conference call will be to provide Trinity Biotech shareholders information regarding the reasons for the proposal, the company's response to the proposal, if any, the qualifications of the replacement directors, and steps that shareholders can take to impose accountability on company management.

The conference call can be accessed in the U.S. by dialing 1-800-899-9949 conference code 2111155.

Thomas J. Reidy, Kansas City, (816) 260-8476


'/>"/>
SOURCE Thomas J. Reidy, Kansas City
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Nile Therapeutics to Present at the 7th Annual BIO Investor Forum
2. GenVault to Present at the BIOCOM Investor Conference
3. Neurobiological Technologies to Present at the BIO Investor Forum in San Francisco on October 30, 2008
4. China Medical Technologies Announces Reporting Dates for the September Quarter Results and Addresses Investor Inquiries
5. BioAtom Inc. To Present at BIOCOM Investor Conference 2008
6. Gerson Lehrman Group and BIO Collaborate to Identify Scientific Expertise for the Seventh Annual BIO Investor Forum
7. Oncothyreon to present at BIO Investor Forum 2008
8. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
9. Celator(R) Pharmaceuticals To Present at 2008 BIO Investor Forum
10. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
11. WaferGen to Present at the Seventh Annual BIO Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... FL (PRWEB) , ... October ... ... (RPS®) today announces publication of a United States multicenter, prospective clinical study ... use, disposable, point-of-care diagnostic test capable of identifying clinically significant acute bacterial ...
(Date:10/11/2017)... CA (PRWEB) , ... October 11, 2017 , ... ... upregulate any gene in its endogenous context, enabling overexpression experiments and avoiding the ... system with small RNA guides is transformative for performing systematic gain-of-function studies. ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... (ADC) therapeutics, today confirmed licensing rights that give it exclusive global access ... developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, an ...
Breaking Biology Technology:
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/28/2017)... 28, 2017 The report "Video ... Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), and ... Global Forecast to 2022", published by MarketsandMarkets, the market ... is projected to reach USD 75.64 Billion by 2022, ... The base year considered for the study is 2016 ...
Breaking Biology News(10 mins):